GBT Announces Participation in Upcoming Investor Conferences

Article Stock Quotes (1)

FREE Breaking News Alerts from StreetInsider.com!

StreetInsider.com Top Tickers, 8/22/2026

1. WMT
2. ROST
3. AAP
4. SPY
5. NVDA

6. AVGO
7. SPCX
8. DE
9. OSIS
10. REAX

Get Alerts GBT Hot Sheet

Price: $68.49 --0%

Overall Analyst Rating:
SELL (= Flat)

Join SI Premium – FREE

SOUTH SAN FRANCISCO, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will participate in fireside chats at the following investor conferences:

Bank of America Securities 2022 Healthcare Conference in Las Vegas, NV on Wednesday, May 11, at 2:40 p.m. P.T.; and
RBC Capital Markets 2022 Global Healthcare Conference in New York, NY on Wednesday, May 18, at 9:00 a.m. E.T.

The fireside chats will be webcast live from GBT’s website at www.gbt.com in the Investors section. Replays of the webcasts will be archived and available for one month following each event.

About Global Blood Therapeutics Global Blood Therapeutics (GBT) is a biopharmaceutical company dedicated to the discovery, development and delivery of life-changing treatments that provide hope to underserved patient communities, starting with sickle cell disease (SCD). Founded in 2011, GBT is delivering on its goal to transform the treatment and care of SCD, a lifelong, devastating inherited blood disorder. The company has introduced Oxbryta® (voxelotor), the first FDA-approved medicine that directly inhibits sickle hemoglobin (HbS) polymerization, the root cause of red blood cell sickling in SCD. GBT is also advancing its pipeline program in SCD with inclacumab, a P-selectin inhibitor in Phase 3 development to address pain crises associated with the disease, and GBT021601 (GBT601), the company’s next generation HbS polymerization inhibitor. In addition, GBT’s drug discovery teams are working on new targets to develop the next generation of treatments for SCD. To learn more, please visit www.gbt.com and follow the company on Twitter @GBT_news.

Contact:Steven Immergut (media)650-410-3258[email protected]

Courtney Roberts (investors)650-351-7881[email protected]